References
- Leppik IE. Variability of antiepileptic medication concentrations and compliance. In: Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991, pp.349–358
- Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273–7
- Garnett WR, Levy B, McLean AM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39:274–9
- Hoppener RJ, Kuyer A, Meijer JW, et al. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21:341–50
- Garnett WR, McLean AM, Zhang Y, et al. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin 2003;19:519–25
- Mirza WU, Rak IW, Thadani VM, et al. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998;51:1727–9
- Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: An open-label, 12- to 36-month continuation study. Clin Ther 2003;25: 2586–96
- May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023–42
- Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70–6
- Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000;41:107–39
- Reinikainen KJ, Keranen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284–9
- McLean A, Browne S, Zhang Y, et al. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J Clin Pharmacol 2001;41:183–6
- Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12:7–15
- Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999;33:39–55
- Begley CE, Lairson DR, Reynolds TF, et al. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 2001;47:205–15
- Garnett WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20:191S–9
- Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000;41(Suppl 5):S37–44
- Buck D, Jacoby A, Baker GA, et al. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997; 6:87–93